Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

4 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

5(50.0%)

Phase 2

4(40.0%)

Phase 3

1(10.0%)

10Total

Phase 1(5)

Phase 2(4)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT06910358Phase 3Active Not Recruiting

Study of Bitopertin in Participants With EPP or XLP (APOLLO)

Role: lead

NCT07187973Phase 1Recruiting

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

Role: lead

NCT07368972Phase 2Recruiting

Study of DISC-0974-201 in Participants With IBD and Anemia

Role: lead

NCT05320198Phase 1Recruiting

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Role: lead

NCT05745883Phase 1Completed

Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia

Role: lead

NCT06985147Phase 2Recruiting

A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

Role: lead

NCT05308472Phase 2Completed

Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP

Role: lead

NCT05883748Phase 2Enrolling By Invitation

HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

Role: lead

NCT06050915Phase 1Completed

A Study of DISC-3405 in Healthy Volunteers

Role: lead

NCT04999527Phase 1Completed

Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects

Role: lead

All 10 trials loaded